Urology | Specialty

Enfortumab Vedotin Shows Superior Efficacy Over Chemo in Previously Treated Urothelial Carcinoma

February 13th 2021

February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.

Avelumab as Frontline Maintenance Maintains OS Benefit in Japanese Subgroup of Advanced Urothelial Cancer

February 11th 2021

February 11, 2021 - Avelumab as frontline maintenance therapy plus best supportive care showed a favorable benefit-risk balance in Japanese patients with advanced urothelial cancer that did not progress on first-line chemotherapy.

test-figure-caption

January 29th 2021

summary

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

October 14th 2020

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial Carcinoma

September 20th 2020

Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.

Immune-Related Biomarkers Linked With OS Benefits of Frontline Maintenance Avelumab in Advanced Urothelial Carcinoma

September 20th 2020

Overall survival benefits of frontline maintenance treatment with avelumab in patients with advanced urothelial cancer were found to be positively associated with biomarkers of immune activity and negativity linked with biomarkers of tumor homeostasis and chronic inflammation.

Bright Future in Advanced Urothelial Cancer

August 26th 2020

Sequencing Considerations in mUC after Frontline IO

August 26th 2020

Metastatic Bladder Cancer: Progression After Maintenance

August 26th 2020

x